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ABSTRACT  
Objectives: Metformin has been reported to reduce the risk of preeclampsia. It 
is also known to influence soluble fms-like tyrosine kinase-1 (sFlt-1) levels, 
which correlate significantly with the gestation of onset and severity of 
preeclampsia. The main aim of this systematic review and meta-analysis was to 
determine whether metformin use is associated with the incidence of 
hypertensive disorders of pregnancy (HDP).  
Methods: MEDLINE (1947 – September 2017), Scopus (1970 – September 
2017) and the Cochrane Library (since inception - September 2017) were 
searched for relevant citations in English language. Randomized controlled 
trials on metformin use, reporting the incidence of preeclampsia or pregnancy 
induced hypertension were included. Studies on populations with a high 
probability of metformin use prior to randomization (type II diabetes or polycystic 
ovary syndrome) were excluded. Random-effects models with Mantel-Haenszel 
were used for subgroup analyses. Moreover, a Bayesian random-effects meta-
regression was used to synthesize the evidence.    
Results: In total, 3337 citations matched the search criteria. After evaluating 
the abstracts and full text review, 15 studies were included in the review. 
Metformin use was associated with a reduced risk of pregnancy induced 
hypertension when compared to insulin (RR: 0.56, 95% CI: 0.37-0.85, I^2=0, 
1260 women) and a non-significantly reduced risk of preeclampsia (RR: 0.83, 
95% CI: 0.60-1.14, I^2=0%, 1724 women). When compared to placebo, 
metformin use was associated with a non-significant reduction of preeclampsia 
(RR: 0.74, 95% CI: 0.09-6.28, I^2=86%, 840 women). Metformin use was also 
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associated with a non-significant reduction of any HDP (RR: 0.71, 95% CI: 0.41-
1.25, I^2=0, 556 women) when compared to glyburide. When studies were 
combined with Bayesian random-effects meta-regression using treatment type 
as a covariate, the posterior probabilities of metformin having a beneficial effect 
for the prevention of preeclampsia, pregnancy induced hypertension and any 
HDP were 92.7%, 92.8% and 99.2%, respectively when compared to any other 
treatment or placebo. 
Conclusions: There is a high probability that metformin use is associated with 
a reduced HDP incidence when compared to other treatments and placebo. The 
small number of studies included in the analysis, the low quality of evidence and 
the clinical heterogeneity preclude the generalization of these results to broader 
populations. Given the clinical importance of this topic and the magnitude of 
effect observed in this meta-analysis, further prospective trials are urgently 
needed.   
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INTRODUCTION 
Preeclampsia is a leading cause of maternal mortality and morbidity which 
imposes a substantial burden on the healthcare system.1 Significant efforts 
have been devoted to developing clinically useful screening methods and 
prevention strategies for preeclampsia. Although the recommended approach to 
screening for preeclampsia is blood pressure monitoring, the ASPRE trial has 
shown that it is possible to predict the development of early-onset preeclampsia 
with good precision using a combination of maternal factors and biomarkers in 
the first trimester of pregnancy.2,3 Early prediction is quite important as aspirin, 
the only proven prevention method for preeclampsia, has a dose- and time-
dependent effect.4 Early prediction and additional interventions could boost the 
beneficial effects of aspirin.5 However, only 12% of all preeclampsia cases are 
early-onset and prediction models show poorer precision for late-onset 
disease.3,6 Furthermore, aspirin failed to show a clinically meaningful effect on 
the development of late-onset preeclampsia where the majority of the disease 
burden lies.7 Therefore, a prevention method targeting both early- and late-
onset preeclampsia is highly desirable. 
 
Metformin is a biguanide that prevents gluconeogenesis in liver and increases 
the sensitivity of the peripheral tissue to insulin. The use of metformin in 
obstetrics is gaining pace as it has been shown to be efficacious in the 
treatment of gestational diabetes and possibly in the prevention of 
preeclampsia.8-10 A plausible mechanism by which metformin, an anti-diabetic 
agent, might prevent preeclampsia is suggested by an in-vivo study by 
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Brownfoot et al., which demonstrated that metformin reduces soluble fms-like 
tyrosine kinase-1 (sFlt-1) levels which correlate significantly with the 
preeclampsia onset and severity.11,12 It has also been suggested that metformin 
may prevent preeclampsia by improving cardiovascular function and limiting 
gestational weight gain.13 Regardless of the underlying mechanism, the clinical 
implications are very important if metformin is proven effective in preventing 
late-onset preeclampsia. However, a randomized trial investigating the effects 
of metformin on the development of preeclampsia as the primary outcome is yet 
to be conducted. The main aim of this systematic review and meta-analysis was 
to determine whether metformin prevents hypertensive disorders of pregnancy. 
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METHODS 
 
Protocol, eligibility criteria, information sources, and search 
This review was performed according to a protocol designed a priori and 
recommended for systematic reviews and meta-analysis.14-18 MEDLINE (1947 – 
September 2017), Scopus (1970 – September 2017) and the Cochrane Library 
(since inception - September 2017) including The Cochrane Database of 
Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effects 
(DARE) and The Cochrane Central Register of Controlled Trials (CENTRAL) 
were searched electronically on September 2017 utilizing combinations of the 
relevant MeSH terms, keywords, and word variants for “metformin”, 
“pregnancy”, “preeclampsia”, “hypertension”, “randomized”, “gestational 
hypertension”. The search was restricted to studies in English language. 
Reference lists of relevant articles and reviews were hand searched for 
additional reports. The PRISMA guidelines were followed.16 The study was 
registered with the PROSPERO database (Registration number 
CRD42017080369). 
 
Study selection, data collection and data items 
Studies were assessed according to the following criteria: population, outcome, 
type of hypertensive disorder, gestational weight gain and gestational age at 
initiation of metformin therapy. Randomized controlled trials reporting the 
incidence of preeclampsia or pregnancy induced hypertension were included. 
Studies in which metformin treatment was received prior to randomization were 
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excluded. All abstracts were independently reviewed by two authors (EK, ES). 
Agreement about potential relevance was reached by consensus, and full-text 
copies of those papers were obtained. The same two reviewers independently 
extracted data regarding the study characteristics and outcomes. 
Inconsistencies were discussed by the reviewers and consensus reached. If 
more than one study was published for the same cohort with identical 
endpoints, the report containing the most comprehensive information on the 
population was included to avoid overlapping populations. Randomized 
controlled trials were included while cohort studies, case control studies, case 
series, case reports, conference abstracts, and editorials were excluded. 
Studies were included in which data on pregnancy outcomes, including the 
incidence of preeclampsia and gestational hypertension could be extracted.  
 
Risk of bias, summary measures and synthesis of the results 
The risk of bias in the included studies was assessed using the Cochrane risk of 
bias tool.17 The quality of the evidence was assessed using the GRADE 
approach developed by the Grading of Recommendations, Assessment, 
Development and Evaluations Working Group. Data on the type of intervention, 
gestational age at randomization, gestational age and the incidence of 
hypertensive disorders, with corresponding participant numbers were extracted 
from each included study. Analysis of the extracted data was performed with 
RStudio (Version 1.0.136, RStudio, Inc). For binary outcomes, a random-effects 
model with Mantel-Haenszel method were used for pooling of studies. Relative 
risks were obtained for binary outcomes. The variance between the studies was 
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tested using the I squared statistic. When the number of included studies was 
adequate, publication bias was explored using funnel plots asymmetry tests (i.e. 
Egger test).19,20 Due to low number of studies in each subgroup analysis, a 
Bayesian meta-regression or meta-analysis were employed to synthesize the 
evidence regarding metformin use and hypertensive disorders of pregnancy 
using the comparator (insulin, glyburide, placebo) as a covariate. A normal 
distribution (N~0,10.000) for the mean effect estimates and a uniform 
distribution (U~0,5) for the variance estimates were used as vague priors for 
Bayesian random effects meta-regression. Posterior probabilities of intervention 
having a protective effect against the hypertensive disorders of pregnancy were 
calculated. A fixed effects method for Bayesian analysis was used when 
posterior density plots for heterogeneity showed minimal between study 
variation (<1 SD). Convergence diagnostics were made with Gelman-Rubin 
statistic and traceplots. All Bayesian computations were performed using 
Markov Chain Monte-Carlo (MCMC) sampler in R. MCMC sampling was run for 
each analysis for 3.000.000 iterations after discarding the first 50000. 
 
RESULTS 
Study selection, characteristics and risk of bias  
In total, 3337 citations matched the search criteria and three additional studies 
were identified via manual search (Figure 1). After removing duplicate and 
irrelevant studies, 52 were retrieved for full text review. Studies were excluded 
due to the outcome reported being not relevant (n=15), study design not 
matching our protocol (n=13) or overlapping populations (n=4). Another study 
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was excluded due to unacceptably high risk of bias21 and 4 studies with 
metformin use prior to randomization22-25, leaving 15 studies to be included in 
the meta-analysis. The methodological characteristics of the included studies 
are shown in Table 1. The participants’ characteristics varied among the 
studies, which included women with gestational diabetes mellitus (13 studies) 
and obese women (2 studies). Metformin was  
compared to insulin (8 studies), placebo (2 studies) and glyburide (5 
studies).10,26-39 The mean gestational age at randomization and the risk 
characteristics differed greatly among the studies (Table 1). The planned 
metformin dose, received metformin dose, additional treatment, and the 
compliance also varied among the studies, contributing to the observed clinical 
heterogeneity (Table 2).  A summary of the qualitative evaluation of the included 
studies according to the Cochrane risk of bias tool is presented in Table 3. All 
trials were considered to be at low risk of blinding bias due to low probability of 
blinding affecting the occurrence of preeclampsia or pregnancy induced 
hypertension.  
 
Synthesis of results 
Studies were grouped according to the comparator treatment and analyzed for 
different outcomes. Metformin use was associated with a reduced risk of 
pregnancy induced hypertension when compared to insulin (RR: 0.56, 95% CI: 
0.37-0.85) (Table4) in women with GDM. Although, the risk estimate for 
preeclampsia (RR: 0.83, 95% CI: 0.60-1.14) was lower with metformin use 
when compared to insulin, the difference didn’t reach statistical significance 
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(Table 4, Supplementary Figure 1). According to Bayesian random-effects 
meta-analysis, the posterior probabilities of metformin having a beneficial effect 
for the prevention of preeclampsia, pregnancy induced hypertension and any 
HDP were 93.5%, 86.7% and 97.7%, respectively (Table 4).   
Metformin use was associated with a non-significant reduction of preeclampsia 
(RR: 0.66, 95% CI: 0.11-3.82), pregnancy induced hypertension (RR: 0.79, 95% 
CI: 0.42-1.49) and any HDP (RR: 0.71, 95% CI: 0.41-1.25) when compared to 
glyburide in women with GDM (Table 1, Supplementary Figure 2). According to 
Bayesian random-effects meta-analysis, the posterior probabilities of metformin 
having a beneficial effect for the prevention of preeclampsia, pregnancy induced 
hypertension and any HDP were 50.7%, 50.0% and 74.3%, respectively (Table 
4).   
When compared to placebo, metformin use was associated with a non-
significant reduction of preeclampsia in obese women (RR: 0.74, 95% CI: 0.09-
6.28) (Table 4, Supplementary Figure 3). The number of studies included in this 
analysis was low (n=2) with high statistical heterogeneity (I^2=86%). According 
to Bayesian random-effects meta-analysis, the posterior probabilities of 
metformin having a beneficial effect for the prevention of preeclampsia, 
pregnancy induced hypertension and any HDP were 46.0%, 43.4% and 43.2%, 
respectively (Table 4).  Due to low number of studies and methodological 
similarities between the studies, a fixed-effects model analysis was also 
performed. The risk of preeclampsia was lower with metformin use in the fixed 
effects model (RR: 0.51, 95%CI: 0.26-0.98) with high statistical heterogeneity 
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(I^2=86%). The posterior probability (fixed-effects Bayesian) for beneficial effect 
was 99.4% (OR: 0.54, 95% credible intervals: 0.25-0.95). 
No studies compared metformin with placebo in women with GDM and also 
there were no studies comparing metformin with insulin in obese women as 
expected. 
When the available evidence was combined with a Bayesian random-effects 
meta-regression using the treatment type as a covariate, the posterior 
probabilities of metformin having a beneficial effect for the prevention of 
preeclampsia, pregnancy induced hypertension and any HDP were 92.7% (OR: 
0.72 95% credible intervals: 0.42-1.16), 92.8% (OR: 0.74, 95% credible 
intervals: 0.43-1.12) and 99.2%( OR: 0.71 95% credible intervals: 0.50-0.98), 
respectively when compared to other treatments (Figure 2). Between study 
variance in these analyses were small (Figure 2, Supplementary Figure 4).  
 
The overall quality of evidence was low. Most analyses were downgraded one 
point for imprecision and at least one point for indirectness (Table 4, 
Supplementary Material). The publication bias wasn’t formally investigated due 
to low number of studies in each subgroup analysis.  
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DISCUSSION 
 
Summary of the main findings 
In this meta-analysis of randomized trials, metformin reduced the risk of, 
pregnancy induced hypertension compared to insulin in women with GDM.  
Also, metformin use was associated with a high probability for the prevention of 
any HPD when compared to other treatments and placebo. The analyses were 
characterized by low number of included studies, significant clinical 
heterogeneity, and low quality of evidence.  
 
Study strengths and limitations 
We included all randomized trials in which metformin was compared to any 
treatment modality or placebo. The total number of studies included in the 
quantitative analysis was modest (n=15). Although we could not perform a 
subgroup analysis for early- and late-onset preeclampsia, metformin 
randomization was before 30 weeks’ gestation in most of the studies included 
indicating that the summary effect we observed is likely due to the prevention of 
late-onset preeclampsia. Another limitation of this analysis was the clinical 
heterogeneity among the included studies. It is important to note that diagnostic 
criteria for the outcome measures differed between studies but the diagnostic 
criteria of preeclampsia and pregnancy induced hypertension are relatively 
similar among the available guidelines. Also, HDP was not the primary outcome 
measure in any of the included studies and metformin was not specifically 
tested for the prevention of HDP. This is an important confounder and the effect 
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observed in these studies could be due to other uncontrolled factors (i.e. 
gestational weight gain). We used both random and fixed effects models for 
studies comparing metformin with placebo which yielded conflicting results. The 
studies included in this analysis were quite similar in their design and execution, 
thus was characterized by low clinical heterogeneity but high statistical 
heterogeneity. However, it is unlikely the summary estimates presented by 
either method are good representations of the real effect. The Bayesian 
random-effects meta-analysis was in agreement with this assessment as the 
posterior estimates were dominated by the vague prior information (posterior 
probability ~50%), indicating the current evidence is too weak to draw firm 
conclusions for this subgroup. The majority of the evidence stemmed from 
studies comparing metformin with insulin in women with GDM. However, the 
magnitude of effect was relatively constant among other comparators but 
without statistical significance, which was probably due to insufficient number of 
included studies. Also, our review comprises two main population of pregnant 
women, i.e. women with GDM and obese women. The results we have obtained 
here is mainly applicable to such populations.  Women with a high probability of 
metformin use prior to randomization (type II diabetes and polycystic ovary 
syndrome) were excluded in this meta-analysis and the results we have 
obtained cannot be applied to these populations.  
 
Comparison with existing literature and research implications  
Although the use of metformin in pregnant women dates back to 1979, it has 
recently become a popular treatment choice for gestational diabetes due to its 
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proven effectiveness, safety in pregnancy, ease of use and high compliance 
rate.40 The effectiveness of metformin compared to insulin in managing 
gestational diabetes was demonstrated in a meta-analysis by Gui et al.41 In a 
subgroup analysis Gui et al. have reported that the prevalence of preeclampsia 
was similar between the metformin and insulin groups (OR: 0.69 95% 
confidence internal: 0.42 to 1.12). However, this analysis included only three 
studies. Two previous meta-analyses by Feng et al. and Butalia et al. 
demonstrated a significant effect of metformin in reducing the incidence of 
preeclampsia in women with diabetes (RR: 0.70, 95% CI: 0.49 to 0.99, RR: 
0.56, 95% CI: 0.37 to 0.85, respectively).9,42 Again, these were subgroup 
analyses within studies aimed at assessing the effects of metformin during the 
treatment of diabetes during pregnancy. Notably, these meta-analyses did not 
report preeclampsia and pregnancy induced hypertension outcomes separately. 
A recent Cochrane review by Brown et al. reported a non-significant reduction in 
the risk of preeclampsia in women with gestational diabetes taking metformin, 
but a significantly reduced risk of gestational hypertension; this is in line with our 
findings.43 In contrast to the findings of the Cochrane review, Alqudah et al. 
found a significant association between metformin use and reduced risk of 
preeclampsia when compared to insulin.44 However, studies involving patients 
with type 2 diabetes were included in that review. Compared to previous 
reviews, we provide the Bayesian estimates in the form posterior probabilities. 
In general, metformin use was associated with a high probability for beneficial 
effect in the prevention of HDP.  Bayesian analysis allows the probabilistic 
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interpretation of results and avoids the problems arising from null hypothesis 
testing (i.e. type I and II errors).  
 
Obesity is a known risk factor for the development of pregnancy induced 
hypertension and preeclampsia. The trials which investigated increasing 
physical activity and limiting gestational weight gain during pregnancy have 
demonstrated a lower incidence of hypertensive disorders of pregnancy.45,46 
The preventive effects of physical activity could be due to an improvement in 
cardiovascular function and/or reduced gestational weight gain. Of note, 
metformin has been reported to have beneficial effects in those at-risk 
women.42,47-49 Improved cardiovascular function and reduced gestational weight 
gain, in addition to its known stabilization of vasoactive mediators,11 could be 
the underlying mechanisms of the beneficial effects of metformin. Weight gain is 
one of the factors that could contribute to clinical heterogeneity we observed in 
this analysis. Future studies on this topic should carefully investigate this factor 
and its association with late-onset preeclampsia in addition to metformin use.  
 
Conclusions  
Metformin is associated with a high probability of preventing of any HPD when 
compared to other treatments. The small number of the included studies and 
their clinical heterogeneity preclude the generalization of these results to 
broader populations. Therefore, randomized trials of metformin use for the 
prevention of preeclampsia are urgently needed. 
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Figure legends 
Figure 1. PRISMA flow diagram of study selection. 
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Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 
 
For more information, visit www.prisma-statement.org. 
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Figure 2. Results of Bayesian random-effects meta-regression using 
treatment type as the covariate.  (Left) Forest plots of studies comparing 
metformin with any other treatment or placebo for the occurrence of 
pregnancy induced hypertension, preeclampsia or any hypertensive disorder 
of pregnancy. (Right) Posterior distribution plots of between study variance. 
Square boxes represent the mean effect estimate and black lines represent 
the 95% credible intervals for individual studies. The diamonds represent the 
summary effect estimates. Between study variance below 1 SD indicates 
low heterogeneity.    
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Supplementary Figure 1. Forest plot of studies comparing metformin 
versus insulin for the occurrence of pregnancy induced hypertension, 
preeclampsia or any hypertensive disorder of pregnancy. 
Supplementary Figure 2. Forest plot of studies comparing metformin 
versus glyburide for the occurrence of pregnancy induced hypertension, 
preeclampsia or any hypertensive disorder of pregnancy. 
Supplementary Figure 3. Forest plot of studies comparing metformin 
versus placebo for the occurrence of pregnancy induced hypertension, 
preeclampsia or any hypertensive disorder of pregnancy. 
Supplementary Figure 4. Forest plot of studies comparing metformin 
versus other drugs or placebo for the occurrence of pregnancy induced 
hypertension, preeclampsia or any hypertensive disorder of pregnancy. 
 
Each study is represented by a line. The box in the middle of the line 
represents the point effect estimate of this particular study. The midpoint of 
the box represents the point effect estimate, that is, the mean effect estimate 
for each study. The area of the box represents the weight given to the study. 
The diamond below the studies represents the overall estimate. The width of 
the line shows the confidence interval (CI) of the effect estimate of individual 
studies. The width of the diamond shows the CI for the overall effect 
estimate. Heterogeneity (I2) = diversity between studies. 
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Table 1. The characteristics of the studies included in this systematic review 
Author Comparator Inclusion criteria  Exclusion criteria No. of 
patients
GA at 
randomization 
(weeks) 
GA at 
delivery 
(weeks) 
Ainuddin 
2015 
Insulin Women with GDM 
not responding to 
diet and exercise 
Contraindication to metformin, fetal 
anomaly, type I or II diabetes, fetal 
growth restriction, positive glucose 
tolerance test before 26 weeks, 
ruptured membranes  
150 29  37 
Chiswick 
2015 
Placebo Obese 
(BMI>30kg/m2) 
women without 
overt diabetes 
Non-Caucasian ethnicity, overt 
diabetes, GDM in previous 
pregnancy, GDM in current 
pregnancy before randomization, 
systemic disease, history of 
preeclampsia prior to 32 weeks, 
434 14  39 
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fetal growth restriction, sensitivity to 
metformin.    
George 
2015 
Glyburide Women with GDM 
not responding to 
diet and exercise 
Type I or II diabetes, currently on 
metformin, multiple pregnancy, fetal 
anomaly, renal or liver dysfunction, 
cardiorespiratory disease, 
malabsorption, sepsis, ruptured 
membranes, preeclampsia or 
gestational hypertension  
159 29 38 
Ijas 2011 Insulin Women with GDM Preeclampsia, essential 
hypertension, fetal growth restriction 
97 30 39 
Moore 2010 Glyburide Women with GDM 
not responding to 
diet and exercise 
Chronic hypertension, substance 
misuse, renal or hepatic disease 
149 29 38 
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Nachum 
2017 
Glyburide Women with GDM 
not responding to 
diet alone 
Women without dating, 
pregestational diabetes, suspected 
fetal growth restriction, major fetal 
malformations 
104 29 38 
Niromanesh 
2012 
Insulin Women with GDM 
not responding to 
diet alone 
Systemic disease, substance abuse, 
overt diabetes, major fetal 
malformations 
160 28 38 
Rowan 
2008 
Insulin Women with GDM 
not responding to 
diet and exercise 
Contraindication to metformin, fetal 
anomaly, gestational hypertension, 
preeclampsia, fetal growth 
restriction, ruptured membranes 
733 30 38 
Spaulonci 
2013 
Insulin Women with GDM 
not responding to 
diet and exercise 
Lost to prenatal follow-up 92 32 38 
Syngelaki Placebo Obese History of GDM, major fetal defect, 400 15 91.5% 
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2016 (BMI>35kg/m2) 
women without 
overt diabetes 
kidney, liver or heart failure, 
hyperemesis gravidarum, sensitivity 
to metformin, metformin use at the 
time of screening, miscarriage 
before randomization.    
term 
delivery 
Tertti 2013 Insulin Women with GDM 
not responding to 
diet alone 
Cardiac or renal insufficiency, liver 
disease, metformin use within 3 
months preceding index pregnancy 
or during pregnancy prior to 
randomization, self-reported fasting 
plasma glucose value >5.5mmol/L 
227 30 39 
Silva 2010 Glyburide Women with GDM 
not responding to 
diet and exercise 
Medication intolerance, fetal 
abdominal circumference above 
97% or below 5%, lack of follow-up, 
fetal malformations 
72 26 92.3% 
term 
delivery 
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Pujara 
2017 
Glyburide Women with GDM 
not responding to 
diet and exercise 
Smoking, assisted reproduction, 
overt diabetes, allergy to metformin, 
fetal anomaly, abdominal 
circumference above 97% or below 
5%,intolerance to medication, lost to 
follow-up, multiple pregnancy, 
randomization delivery interval less 
than 2 weeks 
72 25 38 
Najafian 
2017 
Insulin Women with GDM 
not responding to 
diet and exercise 
Lack of patient satisfaction, overt 
diabetes, multiple pregnancy, 
systemic disease, lack of glycemic 
control under maximum dose of 
metformin 
138 Not reported Not 
reported 
Saleh 2016 Insulin Women with GDM 
not responding to 
Overt diabetes, fetal anomaly, 
obstetric high risk conditions, liver or 
137 28 38 
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diet alone kidney disease, intolerance to 
metformin 
GA: gestational age; GDM: gestational diabetes; BMI: body mass index 
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Table 2. The characteristic of metformin use in the studies included in this systematic review 
Author and year No. women 
requiring adjunct 
treatment, n (%) 
Planned metformin 
dose 
Compliance * Received metformin dose  
Ainuddin 2015 32 (42.7) 500 to 2500 mg Not reported Mean dose: 1950 mg (SD: 540mg) for 
metformin alone group and mean dose: 1910 
mg (SD: 680mg) for metformin plus insulin 
group 
Chiswick 2015 - 500 to 2500 mg 65.3% A metformin dose of 2500mg and 2000mg were 
taken during 38% and 62% of all possible drug 
taking days, respectively. 
George 2015 0 (0) 500 to 2500 mg Not reported The maximum daily dose was 500mg in 58.7%, 
1000mg in 21.3% and >1000mg in 20.0% of 
participants  
Ijas 2011 15 (31.9) 750 to 2250 mg Not reported Not reported 
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Moore 2010 26 (34.7) 500 to 2000 mg Not reported Not reported 
Nachum 2017 9 (17%) 850 to 2250mg Not reported Not reported 
Niromanesh 2012 11 (13.8) 1000 to 2500 mg Not reported Median:1500mg (IQR:  1000 to 2500mg) 
Rowan 2008 168 (46.3) 500 to 2500 mg 69.4% All but one participant received more than 
1000mg with a median dose of 2500mg 
Spaulonci 2013 12 (26.1) 1700 to 2550 mg Not reported The maximum daily dose was 1700mg in 
29.8%, 2550mg in 42.6% of participants 
Syngelaki 2016 - 1000 to 3000 mg 79.5% The maximum daily dose was 3000mg in 
63.5%, 2500mg in 14.2% and 2000 mg in 22.2% 
of participants  
Tertti 2013 23 (20.9) 500 to 2000 mg Not reported Median:1500mg (IQR: 500 to 2000mg ) 
Silva 2010 8 (25.0) 500 to 2500 mg Not reported Mean:1284mg (SD: 535mg) 
Pujara 2017 13(26.0%) 500 to 2500 mg Not reported Not reported 
Najafian 2017 Not reported 500 to 2000 mg Not reported 26% of patients was on 2000mg, 66% was on 
1500mg, 5.9% was on 1000mg and 1% was on 
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500mg 
Saleh 2016 Not reported 500 to 3000mg Not reported Not reported 
*Reported as per individual study protocol  
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Table 3. Assessment of the risk of bias in the included studies according to the Cochrane risk of bias tool 
 
 
 
First author and year 
Sequence 
generation
Allocation 
concealment
Blinding of 
participants
Blinding 
of 
outcome 
assessor 
Incomplete 
outcome data 
Selective 
outcome 
reporting
Other 
bias 
Ainuddin 2015 High High Low Low Low Low Unclear 
Chiswick 2015 Low Unclear Low Low Low Unclear Unclear 
George 2015 Low Low Low Low Low Unclear Unclear 
Ijas 2011 Low Low Low Low Low Unclear Low 
Moore 2010 Low Low Low Low Low Low Unclear 
Nachum 2017 Low Low Low Low Low Low Unclear 
Najafian 2017 Unclear Unclear Low Low Low Low Unclear 
Niromanesh 2012 Low Low Low Low Low Low Unclear 
Pujara 2017 Unclear Unclear Low Low High High Unclear 
Rowan 2008 Low Unclear Low Low Unclear Low Unclear 
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Saleh 2016 Low Unclear Low Low Low High Low 
Silva 2010 Low Low Low Low Low Low Unclear 
Spaulonci 2013 Unclear Unclear Low Low Low High Low 
Syngelaki 2016 Low Low Low Low Low Low Low 
Tertti 2013 Unclear Unclear Low Low Low Low Low 
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Table 4. Meta-analysis of studies comparing metformin with other compounds in women with gestational diabetes or obesity. Posterior probability 
of metformin having a beneficial effect is reported by using a Bayesian random-effect meta-analysis.  
 No. 
included 
studies 
Event/Total 
Metformin 
Event/Total 
Insulin 
RR (95% CI)* I^2 Posterior 
probability 
GRADE 
Metformin vs insulin, women with GDM        
- Outcome: Preeclampsia 8 64/856 82/868 0.83 (0.60-1.14) 0% 93.5%
†
 ⨁⊝⊝⊝ VERY LOW 
- Outcome: PIH 4 31/628 56/632 0.56 (0.37-0.85) 0% 86.7%
† ⨁⨁⨁⊝MODERATE
- Outcome: Any HDP 8 95/856 138/868 0.70 (0.54-0.91) 5% 97.7% ⨁⨁⊝⊝ LOW 
Metformin vs insulin, obese women NA - - - - - -
Metformin vs glyburide, women with GDM        
- Outcome: preeclampsia 1 2/75 3/74 0.66 (0.11-3.82) NA 50.7%
‡
 ⨁⨁⊝⊝ LOW 
- Outcome: PIH 3 14/148 18/155 0.79 (0.42-1.49) 0% 50.0%
†
 ⨁⊝⊝⊝ VERY LOW 
- Outcome: Any HDP 5 18/274 26/282 0.71 (0.41-1.25) 0% 74.3%
† ⨁⨁⊝⊝
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 LOW
Metformin vs glyburide, obese women NA - - - - - -
Metformin vs placebo, women with GDM NA - - - - - -
Metformin vs placebo, obese women        
- Outcome: preeclampsia 2 13/423 25/417 0.74 (0.09-6.28) 86% 46.0%
†
 ⨁⊝⊝⊝ VERY LOW 
- Outcome: PIH 2 34/423 27/417 1.24 (0.76-2.03) 0% 43.4%
† ⨁⨁⨁⊝MODERATE
- Outcome: Any HDP 2 47/423 52/417 0.93 (0.30-2.86) 88% 43.2%
†
 ⨁⊝⊝⊝ VERY LOW 
Metformin vs any drug, all women        
- Outcome: preeclampsia 11 79/1354 110/1359 0.75 (0.52-1.09) 33% 92.7% ¶ ⨁⊝⊝⊝VERY LOW 
- Outcome: PIH 9 79/1199 101/1201 0.79 (0.59-1.04) 0% 92.8% ¶ ⨁⊝⊝⊝ VERY LOW 
- Outcome: Any HDP 15 160/1553 216/1567 0.75 (0.59-0.94) 20% 99.2% ¶ ⨁⊝⊝⊝ VERY LOW 
*Random effects meta-analysis with Mantel-Haenszel method 
†Bayesian random-effects meta-analysis with vague priors (Normal or t-distribution)  
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‡Bayesian ﬁxed-effects meta-analysis with vague priors (Normal or t-distribution) 
¶Bayesian random-effects meta-regression using comparator treatment as a covariate 
PIH: pregnancy induced hypertension, HDP: hypertensive disorders of pregnancy, NA: not available 
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